Bufomix Easyhaler, 80 micrograms/4.5 micrograms/inhalation, inhalation powder Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

bufomix easyhaler, 80 micrograms/4.5 micrograms/inhalation, inhalation powder

orion corporation - budesonide; formoterol fumarate dihydrate - inhalation powder - 80/4.5 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

GLAUMOX acetazolamide (as sodium) 500 mg powder for injection vial Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

glaumox acetazolamide (as sodium) 500 mg powder for injection vial

phebra pty ltd - acetazolamide sodium, quantity: 549.5 mg (equivalent: acetazolamide, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

BREVIBLOC esmolol hydrochloride 2.5 g powder for injection for infusion vial Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

brevibloc esmolol hydrochloride 2.5 g powder for injection for infusion vial

phebra pty ltd - esmolol hydrochloride, quantity: 2500 mg - injection, powder for - excipient ingredients: - supraventricular tachycardia,brevibloc (esmolol hcl) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. brevibloc is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. brevibloc is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Geepenil vet 300 mg/ml Powder and Solvent for Solution for Injection Suurbritannia - inglise - VMD (Veterinary Medicines Directorate)

geepenil vet 300 mg/ml powder and solvent for solution for injection

orion corporation - benzylpenicillin sodium - powder and solvent for solution for injection - antimicrobial - horses

Geepenil vet 300 mg/ml Powder for Solution for Injection Suurbritannia - inglise - VMD (Veterinary Medicines Directorate)

geepenil vet 300 mg/ml powder for solution for injection

orion corporation - benzylpenicillin sodium - powder for solution for injection - antimicrobial - horses

ABRAXANE nanoparticle albumin-bound paclitaxel 100 mg powder for injection (suspension) vial Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

abraxane nanoparticle albumin-bound paclitaxel 100 mg powder for injection (suspension) vial

abraxis bioscience australia pty ltd - paclitaxel, quantity: 100 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

ABRAXANE nanoparticle albumin-bound paclitaxel 250 mg powder for injection (suspension) vial Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

abraxane nanoparticle albumin-bound paclitaxel 250 mg powder for injection (suspension) vial

abraxis bioscience australia pty ltd - paclitaxel, quantity: 250 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.